Interleukin-1 Receptor Antagonist in the Treatment of COVID-19 Induced Cytokine Storm
Journal of Cellular & Molecular Anesthesia,
Vol. 5 No. 3 (2020),
19 October 2020
,
Page 209-210
https://doi.org/10.22037/jcma.v5i3.30630
Abstract
- COVID-19
- SARS-CoV-2
- Cytokine Storm
- Interleukin-1
- Anakinra
- Critically ill.
How to Cite
References
Organization WH. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020: World Health Organization, 2020.
Ko W-C, Rolain J-M, Lee N-Y, et al. Remdesivir for SARS-CoV-2 pneumonia. Int J Antimicrob Agents 2020.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine 2020: 1-3.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 2020; 395(10229): 1033-4.
Dinarello C, Arend W, Sims J, et al. IL-1 family nomenclature. Nat Immunol 2010; 11(11): 973.
Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-50.
Dinarello CA. The interleukin-1 family: 10 years of discovery. Faseb j 1994; 8(15): 1314-25.
Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J Exp Med 1972; 136(1): 128-42.
Rosenstreich DL, Vogel SN, Jacques AR, Wahl LM, Oppenheim JJ. Macrophage sensitivity to endotoxin: genetic control by a single codominant gene. J Immunol 1978; 121(5): 1664-70.
Liao Z, Grimshaw RS, Rosenstreich DL. Identification of a specific interleukin 1 inhibitor in the urine of febrile patients. J Exp Med 1984; 159(1): 126-36.
Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med 2014; 20 Suppl 1: S43-58.
Fisher CJ, Jr., Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22(1): 12-21.
Rajasekaran S, Kruse K, Kovey K, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*. Pediatr Crit Care Med 2014; 15(5): 401-8.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet 2020.
Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology 2020.
Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clinical rheumatology 2009; 28(2): 129-37.
Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med 2016; 44(2): 275-81.
Ramirez J, Canete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf 2018; 17(7): 727-32.
Furst DE. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 2004; 26(12): 1960-75.
- Abstract Viewed: 207 times
- PDF Downloaded: 218 times